<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599426</url>
  </required_header>
  <id_info>
    <org_study_id>2020.NK.MDS-EB</org_study_id>
    <nct_id>NCT04599426</nct_id>
  </id_info>
  <brief_title>Allogenic NK Cell Transfusion Azacitidine MDS-EB</brief_title>
  <official_title>Safety and Efficacy of Allogenic NK Cell Transfusion Combined With Azacitidine Therapy for the MDS-EB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy&#xD;
      for refractory MDS-EB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (PR+CR)</measure>
    <time_frame>3 months</time_frame>
    <description>The proportion of patients with complete response(CR) or partial response(PR) as measured by International Working Group efficacy Criteria for myelodysplastic syndromes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with overall survival(OS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>MDS-EB</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic NK cell regimen group</intervention_name>
    <description>10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.&#xD;
Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15 .</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with refractory high-risk MDS (MDS-EB1 and EB2) who had no effect of 2&#xD;
             courses of desitabine or CAG or desitabine + CAG.&#xD;
&#xD;
          2. Patients with age 15 years to 70 years.&#xD;
&#xD;
          3. KPS greater than or equal to 60.&#xD;
&#xD;
          4. ALT and AST are less than 3 times normal.&#xD;
&#xD;
          5. Total bilirubin less than 1.5mg/dl(25.65umol/L).&#xD;
&#xD;
          6. Serum creatinine less than 2.5mg/dl(221umol/L), or creatinine scavenging ability&#xD;
             greater than or equal to 60 mL/min/1.73 m2.&#xD;
&#xD;
          7. Left ventricular ejection fraction cardiac greater than or equal to 45%,&#xD;
             Echocardiography (ECHO) showed no pericardial effusion, Electrocardiogram (ECG) is&#xD;
             normal.&#xD;
&#xD;
          8. No pleural effusion in lungs.&#xD;
&#xD;
          9. Oxyhemoglobin saturation greater than or equal to 92% in normal environment.&#xD;
&#xD;
         10. Women of child-bearing age have negative urine pregnancy tests before administration&#xD;
             began, and agree to use effective contraception during the trial period up to the last&#xD;
             follow-up.&#xD;
&#xD;
         11. KIR mismatch between patient and umbilical cord blood.&#xD;
&#xD;
         12. Volunteer to participate in the trial and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Malignant tumor patient.&#xD;
&#xD;
          2. Patients who are accompanied by fungal, bacterial, viral, or other uncontrolled&#xD;
             infections or require level 4 isolation. (HBV-DNA quantification and normal liver&#xD;
             function in patients with hepatitis b infection are excluded).&#xD;
&#xD;
          3. Patients with HIV, HCV positive.&#xD;
&#xD;
          4. Patients with central nervous system diseases, including stroke, epilepsy, dementia,&#xD;
             or autoimmune central nervous system disorders.&#xD;
&#xD;
          5. Patients with central nervous system diseases, including stroke, epilepsy, dementia,&#xD;
             or autoimmune central nervous system disorders.&#xD;
&#xD;
          6. Patients receiving anticoagulant therapy or with severe coagulation disorders.&#xD;
&#xD;
          7. According to the researcher's judgment, the drug treatment the patient is receiving&#xD;
             will affect the safety and effectiveness of the study.&#xD;
&#xD;
          8. Patients with allergies or history of allergies to biological agents used in this&#xD;
             program.&#xD;
&#xD;
          9. Lactating or pregnant women.&#xD;
&#xD;
         10. Systemic steroid used within 2 weeks before treatment (except for recent or present&#xD;
             use of inhaled corticosteroids).&#xD;
&#xD;
         11. Patients with other uncontrolled diseases, Investigators think it is not suitable for&#xD;
             the participants.&#xD;
&#xD;
         12. Any circumstance that the investigator considers may increase the risk to the subject&#xD;
             or interfere with the results of the study.&#xD;
&#xD;
         13. Patients participate in other clinical studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chengyun Zheng, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Second Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chengyun Zheng, Ph.D.</last_name>
    <phone>+86-531-85875502</phone>
    <email>chengyun.zheng@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 2nd Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250033</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chengyun Zheng, Ph.D.</last_name>
      <phone>+86-531-85875502</phone>
      <email>chengyun.zheng@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NK cell MDS-EB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

